Our vision is to be a financially robust global leader of medical devices that will enhance and save lives.

+ Financial Results

• Total Revenues of A$40,413,706 (2008-2009) an increase of 869% from last year.
• Net Profit after tax of A$12,806,494 (2008-2009) compared to a loss of A$8,617,238 in the previous year.

+ Commercial Agreements

• July 1, 2008. Exclusive Agreement with sanofi-aventis: Receipt of A$16.4m (€10m) fee in exchange for the exclusive right to negotiate for the purchase of the Unilife Readyto- Fill Syringe, and to bear the costs of its industrialisation subject to the signing of the Industrialisation Agreement and the completion of agreed quarterly milestones.
• June 30, 2009. Industrialisation Agreement with sanofi-aventis: Commitment to complete and fund the A$30m Industrialisation program for the Unilife Ready-to-Fill Syringe. Retained right to negotiate with other pharmaceutical companies within therapeutic drug classes to be negotiated.

+ Proprietary Products

• Unilife Ready-to-Fill Syringe: Industrialisation Program targeted for completion in late 2010 (one year ahead of the originally-projected schedule) with the receipt to-date of A$17m (€10m) in milestone payments.
• Unitract 1mL Syringes: U.S. production commenced on an automated assembly system developed and operated out of Unilife’s FDA-registered manufacturing facility in Pennsylvania. Clearance for U.S. sale and marketing by the FDA.
• Pipeline Products: Significant progress made on additional pipeline safety syringe products targeted for use in healthcare and pharmaceutical markets.

+ Business Expansion

• Consolidation of key commercial and operational functions to Unilife’s facility in Pennsylvania, and the expansion of its world-class team with the appointment of 35 management and professional personnel since July 1, 2008.
• Review underway to establish a major new U.S. production facility with strong support received from the Pennsylvania government.
• Commencement of initial discussions with additional pharmaceutical customers interested in the right to purchase the Ready-to-Fill Syringe.
• Proposed redomiciliation from Australia to the U.S., with a proposed listing on NASDAQ.

All currency is reflected in Australian (A$) dollars unless otherwise stated.